IGXT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 15:56):

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market...

Stats
Today's Volume	81 018.00
Average Volume	91 488.00
Market Cap	26.20M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.50
ATR14	$0.00400 (2.67%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-28	Atai Life Sciences N.v.	Buy	4 053 750	Warrant (Right to Buy)
2024-03-08	Atai Life Sciences N.v.	Buy	1 000 000	Convertible Notes
2023-10-06	Atai Life Sciences N.v.	Buy	8 500 000	Convertible Notes
2024-03-08	Atai Life Sciences N.v.	Buy	4 000 000	Warrant (Right to Buy)
2023-11-28	Atai Life Sciences N.v.	Buy	750 000	Convertible Promissory Note

INSIDER POWER
98.98
Last 94 transactions
Buy: 34 722 521 \| Sell: 605 000

IntelGenx Technologies Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IntelGenx Technologies Financials

Annual	2023
Revenue:	$1.04M
Gross Profit:	$-1.46M (-140.52 %)
EPS:	$-0.0568

Q4	2023
Revenue:	$426 000
Gross Profit:	$-294 000 (-69.01 %)
EPS:	$-0.00790

Q3	2023
Revenue:	$318 000
Gross Profit:	$35 000.00 (11.01 %)
EPS:	$-0.0158

Q2	2023
Revenue:	$133 000
Gross Profit:	$-304 000 (-228.57 %)
EPS:	$-0.0164

Financial Reports:

No articles found.

IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.